New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - factor ii 500 [iu] (approx.); factor ix 500 [iu]; factor x 500 [iu] (approx.) - powder for injection with diluent - active: factor ii 500 [iu] (approx.) factor ix 500 [iu] factor x 500 [iu] (approx.) excipient: antithrombin iii heparin sodium water for injection - treatment and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required. treatment and prophylaxis of bleeding in patients with single or multiple congenital deficiency of factor ix, ii or x when purified specific coagulation factor product is not available.

Israel - English - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency. haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Israel - English - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Israel - English - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 100 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor ii activity; factor vii activity; factor x activity; factor ix activity; protein c activity; protein s antigen - powder and solvent for solution for injection - 250 international unit(s) - blood coagulation factors; coagulation factor ix, ii, vii and x in combination

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor ii activity; factor vii activity; factor x activity; factor ix activity; protein c activity; protein s antigen - powder and solvent for solution for injection - 500 international unit(s) - blood coagulation factors; coagulation factor ix, ii, vii and x in combination

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - factor ii activity; factor vii activity; factor x activity; factor ix activity; protein c activity; protein s antigen - powder and solvent for solution for injection - 1000 international unit(s) - blood coagulation factors; coagulation factor ix, ii, vii and x in combination

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 40 ml - injection, solution - excipient ingredients: - treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - water for injections, quantity: 20 ml - injection, solution - excipient ingredients: - treatment and perioperative prophylaxis of bleedings in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin k antagonists, or in case of overdose of vitamin k antagonists, when rapid correction of the deficiency is required.

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - factor ix, human - powder and solvent for solution for injection - 500 international unit(s) - blood coagulation factors; coagulation factor ix